Process for the manufacture of HMG-CoA reductase inhibitors

US7371865B2 · kind B2 · utility

Assignee

• Novartis Pharmaceuticals Corporation · US

Inventors

• Murat Acemoglu · Basel, CH
• Bernhard Riss · Huningue, FR

Key dates

• Filing date: Jan 30, 2003
• Grant date: May 13, 2008
• Expiry date: Dec 11, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/07
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention relates to a process for the manufacture of a compound of formulaor a salt, especially a pharmaceutically acceptable salt with a base, thereof or a lactone thereof wherein the element represents —CH2—CH2— or —CH═CH— and R represents a cyclic residue.